Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)     LONDON & KENILWORTH, N.J.–(BUSINESS WIRE)–GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 […]

PARIS – After experimental multiple sclerosis drug vatelizumab failed to meet its primary endpoints in a mid-stage trial, Sanofi AG (SNY) said it has dropped plans to develop the drug with India-based Glenmark Pharmaceuticals.   During a second-quarter results analysis with media members, Glenmark revealed that Sanofi was terminating the development agreement for vatelizumab, also […]

The U.S. Food and Drug Administration expanded the use of Bristol-Myers Squibb Co’s skin cancer drug, Yervoy, as an additional therapy for patients with late-stage melanoma. This approval extends Yervoy’s use to patients with stage III melanoma, who have a high risk of recurrence after surgery, the agency said on Wednesday. Due to the potential […]

NGF Antibody Fasinumab Currently in Phase 2/3 Osteoarthritis Trial   Tarrytown, N.Y., Oct. 1, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration with Mitsubishi Tanabe Pharma Corporation (TSE: 4508) (MTPC) providing MTPC with exclusive development and commercial rights to fasinumab (REGN475), Regeneron’s NGF antibody in late-stage development for musculoskeletal pain. Under […]

BERKELEY, Calif. – Swiss-based Novartis AG (NVS) struck a deal worth more than $500 million with XOMA Corporation (XOMA) to acquire rights to the company’s anti-transforming growth factor-beta (TGFb) antibody program, Xoma announced this morning. Under terms of the deal, Xoma will receive $37 million in upfront payments, with the remaining $480 million in regulatory […]

Study Evaluated Efficacy and Safety of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer Primary Efficacy Analysis Demonstrates Clinical Equivalence; Safety, Immunogenicity Comparable to Bevacizumab   THOUSAND OAKS, Calif. and DUBLIN, Sept. 23, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced a Phase 3 study […]

Merck & Co. (MRK) enhanced its oncology pipeline with the $605 million acquisition of privately-held Israeli biotech company cCam Biotherapeutics, which is focused on the development of cancer immunotherapies.   With the acquisition of the five-year-old cCam, Merck will add that company’s lead product CM-24, a monoclonal antibody (mAb) that targets CEACAM1, a “checkpoint” protein […]